| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | 0.02 | 0.9 |
| mRNA | AMG-706 | FIMM | pan-cancer | AAC | 0.019 | 0.9 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |